Provide a common HPI for a patient with COPD who has been having symptoms of bacterial pneumonia that started one week ago.
Doximity GPT
History of Present Illness:

The patient is a [age]-year-old [male/female] with a known history of Chronic Obstructive Pulmonary Disease (COPD) who presents with symptoms suggestive of bacterial pneumonia. The patient reports that the symptoms began approximately one week ago and have progressively worsened. Initially, the patient noticed increased dyspnea on exertion, which has now progressed to dyspnea at rest. Additionally, there has been a productive cough with greenish sputum, accompanied by pleuritic chest pain.

The patient also notes experiencing fever and chills, with the highest recorded temperature being 101.5°F. Fatigue and malaise have significantly increased, and the patient has had difficulty performing daily activities due to shortness of breath. There are no reports of hemoptysis. The patient denies any recent travel, known sick contacts, or changes in medication.

The patient has a history of frequent COPD exacerbations, usually requiring antibiotics and steroids. The last exacerbation was [X] months ago. The patient is currently using [list of COPD medications, e.g., inhalers, nebulizers, etc.], but reports that these medications have not provided adequate relief for the current symptoms.

Review of systems is otherwise negative except for the aforementioned symptoms. The patient is concerned about the severity and progression of the symptoms and seeks further evaluation and management.

Which class of antibiotics should I consider for a patient with recurrent bacterial pneumonia who has a penicillin allergy and significant liver disease? Provide relevant references.
Doximity GPT

When considering antibiotic therapy for a patient with recurrent bacterial pneumonia who has a penicillin allergy and significant liver disease, it is essential to choose a class of antibiotics that is effective against the likely pathogens and has a favorable safety profile given the patient's liver condition. Here are some options and considerations:


1. Macrolides (e.g., Azithromycin, Clarithromycin):

• Advantages: Effective against common respiratory pathogens, including atypical bacteria.

• Considerations: Azithromycin is generally preferred over clarithromycin in patients with liver disease due to its less extensive hepatic metabolism and fewer drug interactions.

• References:

• Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., ... & Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases, 44(Supplement_2), S27-S72

• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

2. Tetracyclines (e.g., Doxycycline):

• Advantages: Broad-spectrum activity, including effectiveness against atypical pathogens.

• Considerations: Doxycycline is primarily excreted unchanged in the feces, which makes it a safer option for patients with liver disease.

• References:

• Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., ... & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67.

• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

3. Fluoroquinolones (e.g., Levofloxacin, Moxifloxacin):

• Advantages: Broad-spectrum activity, including against Gram-negative and atypical bacteria.

• Considerations: These drugs are metabolized by the liver to varying extents, but they can be used with caution in patients with liver disease. Moxifloxacin is less dependent on renal excretion compared to other fluoroquinolones.

• References:

• File, T. M., & Marrie, T. J. (2010). Burden of community-acquired pneumonia in North American adults. Postgraduate Medicine, 122(2), 130-141.

• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

Each patient's clinical scenario is unique, and it is crucial to consider the specific details of their medical history, the severity of their liver disease, potential drug interactions, and local antibiotic resistance patterns. Consulting with a specialist in infectious diseases or clinical pharmacology may also be beneficial in complex cases.

Write a letter to an insurance company appealing the denial of empagliflozin for a patient with worsening heart failure. Please include relevant evidence in the letter supporting empagliflozin and include relevant recent data and citations at the bottom.
Doximity GPT

Jason Moore, MD
Oncology
500 3rd Street, #510
San Francisco, CA, 94107

August 21, 2024

Insurance Company Name
Insurance Company Address
City, State, ZIP Code

Re: Appeal for Coverage of Empagliflozin for [Patient’s Name]
Policy Number: [Policy Number]
Claim Number: [Claim Number]

Dear Sir/Madam,

I am writing to formally appeal the recent denial of coverage for empagliflozin (Jardiance) for my patient, [Patient’s Name], who has been diagnosed with worsening heart failure. As [Patient’s Name]'s treating physician, I believe that empagliflozin is a medically necessary treatment that could significantly improve their condition and quality of life.

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that has been demonstrated to provide substantial benefits in patients with heart failure, regardless of diabetic status. The decision to prescribe empagliflozin was based on robust clinical evidence and guidelines, which I will outline below.

Clinical Evidence Supporting Empagliflozin in Heart Failure:

1.
EMPEROR-Reduced Trial (2020):

This landmark trial showed that empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with reduced ejection fraction. The study included over 3,700 patients and demonstrated a 25% relative risk reduction in the primary composite endpoint (Packer et al., 2020).

2.
EMPEROR-Preserved Trial (2021):

This trial extended the benefits of empagliflozin to patients with preserved ejection fraction. The results indicated a significant reduction in the combined risk of cardiovascular death or hospitalization for heart failure, making empagliflozin the first therapy to show benefit in this patient population (Anker et al., 2021).

3.
American College of Cardiology (ACC) Guidelines:

The ACC updated its guidelines to recommend SGLT2 inhibitors, including empagliflozin, for patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of hospitalization and cardiovascular death (Heidenreich et al., 2022).

Given the overwhelming evidence and the guideline recommendations, empagliflozin is not only appropriate but essential for the management of [Patient’s Name]'s worsening heart failure. Denying coverage for this medication undermines the current standard of care and places [Patient’s Name] at increased risk of adverse outcomes.

I urge you to reconsider your decision to deny coverage for empagliflozin. This medication is critical for [Patient’s Name]'s treatment plan and overall prognosis. Please find attached the relevant clinical trial data and guidelines supporting the use of empagliflozin in heart failure.

Thank you for your attention to this matter. I look forward to your prompt and favorable response.

Sincerely,

Jason Moore, MD
Oncology
500 3rd Street, #510
San Francisco, CA, 94107
Phone: [Phone Number]
Fax: [Fax Number]

References:

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413-1424.

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & Zannad, F. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451-1461.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263-e421.

Write a rap battle between cardiology and nephrology about fluid management.
Doximity GPT
Cardiology:

Yo, it's Cardiology stepping to the mic, Gonna show Nephrology how to do it right. When it comes to fluid, I'm the king of the game, Managing the heart, yo, remember my name.

Got my stethoscope, echocardiogram in hand, I keep the rhythm of the heart, understand? Diuretics, ACE inhibitors, I prescribe with flair, Keep that blood pressure down, ain't nothing to compare.

Fluid overload? I see it in my sleep, CHF patients, my skills run deep. Pulmonary edema, I clear up that mess, With my precise treatment, you can call me the best.

Nephrology:

Hold up, Cardiology, you think you're the boss? In the fluid game, you just took a loss. I'm Nephrology, the kidneys are my domain, Filtering that blood, yo, I reign.

I manage electrolytes, keep the balance just right, With my dialysis machine, I bring the light. When the GFR drops, I'm the one they call, In the world of fluid, man, I do it all.

Hyperkalemia? I handle that with ease, Adjusting medications, bringing patients peace. Renal replacement therapy, I've got the know-how, In the fluid management world, you better take a bow.

Cardiology:

You might filter blood, but I pump it with pride, Keeping circulation strong, that's my ride. I keep the heart beating steady and true, Without me, Nephrology, what would you do?

I catch the early signs of fluid distress, With my interventions, I prevent the mess. Beta-blockers, digoxin, I got the tools, In the fluid management school, I set the rules.

Nephrology:

You may pump the blood, but I keep it pure, Without my kidneys, your patients can't endure. I balance the sodium, the water, the waste, In the fluid management race, I set the pace.

I handle AKI, CKD with finesse, With my nephron knowledge, I clean up the mess. Fluid resuscitation, electrolyte control, In this rap battle, Nephrology takes the gold.

Cardiology:

Respect to the kidneys, but don’t forget the heart, Without my rhythm, you wouldn't even start. Together we manage, together we thrive, In the world of medicine, we keep patients alive.

Nephrology:

True that, Cardiology, we make a strong team, In the fluid management dream, we reign supreme. Together we balance, together we care, For every patient, we’re the ultimate pair.

Skip to main contentDownload App

Doximity GPT

Your Free, HIPAA-Compliant Workflow Assistant

Try Now
Simplifying chart notes, clinical research, and patient education — anytime, anywhere.

Why Doximity GPT?

  • Free Access

    Use Doximity GPT, powered by the latest AI models, available for free to U.S. clinicians and medical students.

  • HIPAA-Compliant

    Securely manage patient information with full adherence to HIPAA privacy standards.

  • Task Management

    Streamline charting, letter writing, clinical questions, patient education materials, and more.

  • EHR Compatibility

    Quickly copy and paste outputs directly into your EHR for faster documentation.

  • Workflow Integrations

    Send outputs securely through Dialer text or Doximity fax, maintaining HIPAA compliance.

  • Prompt Library

    Access tailored prompts for your specialty, ensuring precise and relevant communication.

Clinicians’ trusted tool for reducing redundancy

What clinicians are saying about Doximity GPT

4.8 out of 5 stars • 170K ratings

4.7 out of 5 stars • 6.8K ratings

Cut the scut and lighten your workload.

Over 1.5 million tasks completed for clinicians with Doximity GPT

Try Now